Bio-Path Holdings, Inc. (BPTH)
OTCMKTS · Delayed Price · Currency is USD
0.0629
+0.0005 (0.80%)
At close: Apr 15, 2026
Bio-Path Holdings Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
1
Market Cap
587.62K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sorrento Therapeutics | 64.27M |
| Emmaus Life Sciences | 12.45M |
| SQZ Biotechnologies Company | 12.12M |
| EV Biologics | 9.47M |
| Scorpius Holdings | 1.72M |
| Halberd | 6.94K |
Bio-Path Holdings News
- 11 months ago - Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25 - Newsfile Corp
- 11 months ago - Bio-Path Holdings Provides Clinical and Operational Update - GlobeNewsWire
- 11 months ago - Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025 - GlobeNewsWire
- 1 year ago - Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients - GlobeNewsWire
- 1 year ago - Bio-Path Holdings Reports Full Year 2024 Financial Results - GlobeNewsWire
- 1 year ago - Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients - GlobeNewsWire
- 1 year ago - Bio-Path Holdings Provides Key Clinical Updates - GlobeNewsWire
- 1 year ago - Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia - GlobeNewsWire